- The three new biotech indexes could provide investors with a new way to
benefit from the aggressive growth of these three lucrative biotechnology
sub-sectors.
Boston, Massachusetts, November 30, 2015: Vasuda Indices, a subsidiary of Vasuda Capital Management, a Boston-based biotechnology focused investment management firm announced the launch of three new biotechnology sub-sector indexes.
The three indices are:
1. Vasuda Emerging Oncology Breakthroughs Index
2. Vasuda Rare Disease Biotechnology Marvels Index
3. Vasuda Select Orphan Drug Breakthroughs Index
“Oncology, rare disease and orphan drug sub-sectors have historically out-performed the broad biotechnology sector due to the pricing power of these companies and M&A activity. We expect these indexes to be representative of these lucrative biotech sub-sectors. Live quotes for these indexes are available on Bloomberg and Reuters terminals, and our webpage. The indexes are available for licensing to create financial products like ETFs. We expect that financial instruments based on these indexes will allow investors to participate in the aggressive growth of these three sub-sectors.”- said Dr. Bhavneesh Sharma MD, who is the Principal and Investment Manager of Vasuda Indices and Vasuda Capital Management and also holds an MBA in finance from the New York University’s Stern School of Business.
“Vasuda Emerging Oncology Breakthroughs Index consists of micro to mid-cap US listed companies with majority of current or future expected revenue from oncology treatment products. We believe that It is a better representative of the US oncology treatment sector than Loncar Cancer Immunotherapy Index. Our oncology index covers cancer immunotherapy as well as therapeutic areas like targeted therapies, antibody-drug conjugates which are not covered by the Loncar Index. Moreover, Loncar Index consist of companies like Pfizer, Novartis and AstraZeneca whose major current or future expected revenue is not from oncology treatment products. No other equity index representing the rare disease and orphan drug sub-sectors exists in the US so far.”- said Dr. Sharma.
More information about these indexes is available at the website:
http://www.vasudaindices.com
About Vasuda Indices and Vasuda Capital Management: Vasuda Indices, LLC is a wholly owned subsidiary of Vasuda Capital Management, a Greater Boston-based biotechnology-focused investment management firm. The firm was founded by Dr. Bhavneesh Sharma, a physician with an MBA in finance from the New York University’s Stern School of Business. The firm operates Vasuda Life Sciences Fund, LP, a biotechnology focused private investment management firm and is in the process of registration as Investment Advisor in Massachusetts.
Boston, Massachusetts, November 30, 2015: Vasuda Indices, a subsidiary of Vasuda Capital Management, a Boston-based biotechnology focused investment management firm announced the launch of three new biotechnology sub-sector indexes.
The three indices are:
1. Vasuda Emerging Oncology Breakthroughs Index
2. Vasuda Rare Disease Biotechnology Marvels Index
3. Vasuda Select Orphan Drug Breakthroughs Index
“Oncology, rare disease and orphan drug sub-sectors have historically out-performed the broad biotechnology sector due to the pricing power of these companies and M&A activity. We expect these indexes to be representative of these lucrative biotech sub-sectors. Live quotes for these indexes are available on Bloomberg and Reuters terminals, and our webpage. The indexes are available for licensing to create financial products like ETFs. We expect that financial instruments based on these indexes will allow investors to participate in the aggressive growth of these three sub-sectors.”- said Dr. Bhavneesh Sharma MD, who is the Principal and Investment Manager of Vasuda Indices and Vasuda Capital Management and also holds an MBA in finance from the New York University’s Stern School of Business.
“Vasuda Emerging Oncology Breakthroughs Index consists of micro to mid-cap US listed companies with majority of current or future expected revenue from oncology treatment products. We believe that It is a better representative of the US oncology treatment sector than Loncar Cancer Immunotherapy Index. Our oncology index covers cancer immunotherapy as well as therapeutic areas like targeted therapies, antibody-drug conjugates which are not covered by the Loncar Index. Moreover, Loncar Index consist of companies like Pfizer, Novartis and AstraZeneca whose major current or future expected revenue is not from oncology treatment products. No other equity index representing the rare disease and orphan drug sub-sectors exists in the US so far.”- said Dr. Sharma.
More information about these indexes is available at the website:
http://www.vasudaindices.com
About Vasuda Indices and Vasuda Capital Management: Vasuda Indices, LLC is a wholly owned subsidiary of Vasuda Capital Management, a Greater Boston-based biotechnology-focused investment management firm. The firm was founded by Dr. Bhavneesh Sharma, a physician with an MBA in finance from the New York University’s Stern School of Business. The firm operates Vasuda Life Sciences Fund, LP, a biotechnology focused private investment management firm and is in the process of registration as Investment Advisor in Massachusetts.
